Singapore, November 29, 2007 -- Aida Pharmaceuticals, Inc. today announced that the company has successfully completed Phase II field testing of its anti-cancer drug, Rh-Apo2L.
The product of over a decade of research, Rh-Apo2L is intended to be a new drug therapy using a recombinant protein produced by genetic engineering. The drug is designed as a highly-targeted therapy with direct function on cancer cells. Assuming successful completion of all testing phases and approval of the drug by China's State Food and Drug Administration (SFDA), Aida expects to have Rh-Apo2L on the market during the third quarter of 2008.
Phase 2 testing results thus far have shown strong efficacy in treating lung cancer (non-small cell), non-Hodgkins lymphoma, stomach cancer, pancreatic cancer and kidney cancer. Shanghai Qiaer, Aida's research subsidiary, has reduced the key cancer targets to the three main diseases which Rh-Apo2L has shown the most efficacy and which have the most market potential. These three cancer targets will be announced at a later date, pending successful trials. Formal results will also be released after clinical tests are completed. After that, the company will apply for the approval of commencement of Phase III clinical trials from SFDA.
|